CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Therapeutic Substitution of Drugs for the Treatment of Tuberculosis: Guidelines

Last updated: June 29, 2020
Project Number: RB1500-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What are the evidence-based guidelines regarding the therapeutic substitution of different drugs for the treatment of tuberculosis when there is a shortage of, or limited access to, the first line treatment?
  2. What are the evidence-based guidelines regarding the therapeutic substitution of different drugs for the treatment of tuberculosis when there is an intolerance of the first line treatment?
  3. What are the evidence-based guidelines regarding the therapeutic substitution of different drugs for the treatment of tuberculosis when there is resistance to one of the drugs in the first line treatment?

Key Message

Three evidence-based guidelines were identified regarding the therapeutic substitution of different drugs for the treatment of tuberculosis when there is resistance to one of the drugs in the first line treatment. No relevant evidence-based guidelines were identified regarding the therapeutic substitution of different drugs for the treatment of tuberculosis when there is a shortage or intolerance of the first line treatment